The Usability & Feasibility of the Oshi 2.0 Platform for IBD Patients
Research type
Research Study
Full title
The Usability & Feasibility of the Oshi Health Remote Monitoring & Disease Management Platform for Patients with Inflammatory Bowel Disease
IRAS ID
270515
Contact name
Charles Lees
Contact email
Sponsor organisation
Oshi Health, Inc
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Brief Background: Inflammatory Bowel Disease (IBD), including Crohn’s Disease (CD) and Ulcerative Colitis (UC), is a chronic disease marked by inflammation in the gastrointestinal tract affecting 515K people in the UK and costing an estimated ~£720 million per year. IBD patients suffer from a debilitating, progressive, chronic disease exacerbated by an inadequate standard of care that results in several issues in the management of their disease, including delays in diagnosis, lack of monitoring and timely intervention, and poor management of co-morbid psychological diseases such as depression and anxiety. In addition, poor care management results in low medication adherence, low compliance with care guidelines and suboptimal treatments, which, at high rates, either do not work initially or lose response over time.
Leveraging digital technology to enable remote monitoring for IBD patients is a huge area of untapped potential to optimize the treatment and care of IBD patients, delivering improved outcomes and enhanced cost savings. In this study, we aim to pilot test and determine the impact of a remote monitoring platform that allows patients to track their symptoms on an ongoing basis, enables the connectivity between patients and their providers, and generates alerts to initiate a timely follow-up action to prevent the worsening of outcomes.
Brief Methods: This is an observational study in which a total of 100 IBD patients, composed of 50 Newly Diagnosed Patients and 50 New Biologics Patients will be onboarded onto the Oshi remote monitoring platform, and will be followed for a period of 6 months. The impact of the platform on outcomes will be determined through questionnaires / surveys that are administered at baseline, month 2, month 4, and month 6 of the study.
REC name
North East - Newcastle & North Tyneside 2 Research Ethics Committee
REC reference
19/NE/0282
Date of REC Opinion
10 Sep 2019
REC opinion
Favourable Opinion